Shuttle Pharmaceuticals Holdings, Inc. announced the dismissal of Forvis Mazars, LLP as its independent registered public accounting firm. The decision was approved by the company's Audit Committee and Board of Directors on October 16, 2026, and will be effective after the company files its Form 10-Q for the quarter ended September 30, 2026. A successor has not yet been appointed.
Key Details
- No Disagreements: The company stated there were no disagreements with Forvis Mazars on any matter of accounting principles, financial statement disclosure, or auditing scope during the last two fiscal years.
- Going Concern: Forvis Mazars' audit reports for fiscal years 2024 and 2025 included an explanatory paragraph expressing substantial doubt about the company's ability to continue as a going concern.
- Material Weaknesses: The filing notes that previously disclosed material weaknesses in internal controls over financial reporting were discussed between the company's Audit Committee and Forvis Mazars.